R. Colle, R. Cohen, D. Cochereau, A. Duval, O. Lascols et al., Immunotherapy and patients treated for cancer with microsatellite instability, Bulletin du Cancer, vol.104, issue.1, pp.42-51, 2017.
DOI : 10.1016/j.bulcan.2016.11.006
URL : https://hal.archives-ouvertes.fr/hal-01419557

T. Adar, L. Rodgers, K. Shannon, M. Yoshida, T. Ma et al., A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome, Modern Pathology, vol.31, issue.3, 2017.
DOI : 10.1200/JCO.2012.45.1674

K. Newton, N. Jorgensen, A. Wallace, D. Buchanan, F. Lalloo et al., promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC), Journal of Medical Genetics, vol.20, issue.(1 Pt 1), pp.789-96, 2014.
DOI : 10.1016/j.ccr.2011.07.003
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159427/pdf

M. Parsons, D. Buchanan, B. Thompson, J. Young, and A. Spurdle, methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification, Journal of Medical Genetics, vol.49, issue.3, pp.151-158, 2012.
DOI : 10.1136/jmedgenet-2011-100714

J. Cunningham, E. Christensen, D. Tester, C. Kim, P. Roche et al., Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability, Cancer Res, vol.58, pp.3455-3460, 1998.

D. Sargent, S. Marsoni, G. Monges, S. Thibodeau, R. Labianca et al., Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer, Journal of Clinical Oncology, vol.28, issue.20, pp.3219-3245, 2010.
DOI : 10.1200/JCO.2009.27.1825

T. André, A. Gramont, . De, D. Vernerey, B. Chibaudel et al., Mutation and Mismatch Repair Status of the MOSAIC Study, Journal of Clinical Oncology, vol.33, issue.35, pp.4176-87, 2015.
DOI : 10.1200/JCO.2015.63.4238

D. Tougeron, G. Mouillet, I. Trouilloud, T. Lecomte, R. Coriat et al., Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study, Journal of the National Cancer Institute, vol.108, issue.7, 2016.
DOI : 10.1093/jnci/djv438

F. Sinicrope, N. Foster, S. Thibodeau, S. Marsoni, G. Monges et al., DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy, JNCI Journal of the National Cancer Institute, vol.103, issue.11, pp.863-75, 2011.
DOI : 10.1093/jnci/djr153

W. Brueckl, C. Moesch, T. Brabletz, C. Koebnick, C. Riedel et al., Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy, Anticancer Res, vol.23, pp.1773-1780, 2003.

D. Guetz, G. Mariani, P. Cucherousset, J. Benamoun, M. Lagorce et al., Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer, Anticancer Res, vol.27, pp.2715-2719, 2007.

B. Tran, S. Kopetz, J. Tie, P. Gibbs, Z. Jiang et al., Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, vol.28, issue.15 suppl, pp.4623-4655, 2011.
DOI : 10.1200/JCO.2009.23.3452

M. Koopman, G. Kortman, L. Mekenkamp, M. Ligtenberg, N. Hoogerbrugge et al., Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, British Journal of Cancer, vol.154, issue.2, pp.266-73, 2009.
DOI : 10.1200/JCO.2003.03.123
URL : http://www.nature.com/bjc/journal/v100/n2/pdf/6604867a.pdf

K. Fujiyoshi, G. Yamamoto, T. Takenoya, A. Takahashi, Y. Arai et al., Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor, Anticancer Research, vol.37, issue.1, pp.239-286, 2017.
DOI : 10.21873/anticanres.11313

S. Venderbosch, I. Nagtegaal, T. Maughan, C. Smith, J. Cheadle et al., Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies, Clinical Cancer Research, vol.20, issue.20, pp.5322-5352, 2014.
DOI : 10.1158/1078-0432.CCR-14-0332

D. Le, J. Uram, H. Wang, B. Bartlett, H. Kemberling et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, vol.372, issue.26, pp.2509-2529, 2015.
DOI : 10.1056/NEJMoa1500596

M. Overman, R. Mcdermott, J. Leach, S. Lonardi, H. Lenz et al., Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, The Lancet Oncology, vol.18, issue.9, pp.10-1016, 2017.
DOI : 10.1016/S1470-2045(17)30422-9

F. Giardiello, J. Allen, J. Axilbund, C. Boland, C. Burke et al., Guidelines on Genetic Evaluation and Management of Lynch Syndrome, Diseases of the Colon & Rectum, vol.57, issue.8, pp.502-528, 2014.
DOI : 10.1097/DCR.000000000000000

E. Stoffel, P. Mangu, S. Gruber, S. Hamilton, M. Kalady et al., Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk???Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines, Journal of Clinical Oncology, vol.33, issue.2, pp.209-226, 2015.
DOI : 10.1200/JCO.2014.58.1322

A. French, D. Sargent, L. Burgart, N. Foster, B. Kabat et al., Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer, Clinical Cancer Research, vol.14, issue.11, pp.3408-3423, 2008.
DOI : 10.1158/1078-0432.CCR-07-1489

J. Taieb, A. Zaanan, L. Malicot, K. Julié, C. Blons et al., Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab, JAMA Oncology, vol.2, issue.5, p.643, 2016.
DOI : 10.1001/jamaoncol.2015.5225
URL : https://hal.archives-ouvertes.fr/hal-01427989

J. Goldstein, B. Tran, J. Ensor, P. Gibbs, H. Wong et al., Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H), Annals of Oncology, vol.25, issue.5
DOI : 10.1093/annonc/mdu100

A. Roth, S. Tejpar, M. Delorenzi, P. Yan, R. Fiocca et al., in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial, Journal of Clinical Oncology, vol.28, issue.3, pp.466-74, 2010.
DOI : 10.1200/JCO.2009.23.3452

V. Popovici, E. Budinska, S. Tejpar, S. Weinrich, H. Estrella et al., -Mutant???Like Population of Patients With Colon Cancer, Journal of Clinical Oncology, vol.30, issue.12, pp.1288-95, 2012.
DOI : 10.1200/JCO.2011.39.5814

J. Guinney, R. Dienstmann, X. Wang, A. De-reyniès, A. Schlicker et al., The consensus molecular subtypes of colorectal cancer, Nature Medicine, vol.228, issue.11, pp.1350-1356, 2015.
DOI : 10.1186/gb-2004-5-10-r80

J. Balmaña, F. Balaguer, A. Cervantes, and D. Arnold, Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines, Ann Oncol, vol.24, 2013.

D. Le, J. Uram, H. Wang, B. Bartlett, H. Kemberling et al., Programmed death-1 blockade in mismatch repair deficient colorectal cancer, J Clin Oncol, vol.34, 2016.